A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
← catalyst calendarNCT07066657 · readout ≤ 589 d
Sponsored by ArriVent BioPharma, Inc. (industry) · AVBP — their whole pipeline →. With Lepu Biopharma Co., Ltd..
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
572estimated
Sites
21
Countries
China, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-25 | actual | When the study began enrolling |
| Primary completion | Mar 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Locally Advanced or Metastatic Solid Tumors
- Colorectal Cancer
- Gastric Cancer
- Pancreatic Cancer
Interventions
- Drug: MRG007 — also filed as ARR-217
- Drug: MRG007 and Bevacizumab — also filed as ARR-217
Primary outcomes
what the primary-completion date above is the date OFDose Limiting Toxicity (DLT) - Phase Ia
measured Baseline to Day 21 of the first treatment cycle
Serious Adverse Events (SAEs)
measured Baseline to 30 days after the last dose of study treatment
Treatment-Emergent Adverse Event (TEAE)
measured Baseline to 30 days after the last dose of study treatment
Treatment-Related Adverse Event
measured Baseline to 30 days after the last dose of study treatment
Objective Response Rate (ORR) as assessed by investigator - Phase Ib
measured Baseline to study completion (up to 24 months)
Permalink · AVBP's whole pipeline · Catalyst calendar · Every registered study · What changed